Your browser doesn't support javascript.
loading
Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial.
Razquin, Cristina; Ruiz-Canela, Miguel; Wernitz, Andreas; Toledo, Estefania; Corella, Dolores; Alonso-Gómez, Ángel; Fitó, Montse; Gómez-Gracia, Enrique; Estruch, Ramón; Fiol, Miquel; Lapetra, José; Serra-Majem, Lluis; Ros, Emilio; Arós, Fernando; Salas-Salvadó, Jordi; Schulze, Matthias B; Martinez-Gonzalez, Miguel A.
Afiliación
  • Razquin C; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.
  • Ruiz-Canela M; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Wernitz A; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.
  • Toledo E; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Corella D; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
  • Alonso-Gómez Á; Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain.
  • Fitó M; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Gómez-Gracia E; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Estruch R; Department of Preventive Medicine, Universidad de Valencia, Valencia, Spain.
  • Fiol M; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Lapetra J; Department of Cardiology, Hospital Universitario de Álava, Vitoria, Spain.
  • Serra-Majem L; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Ros E; Unit of Cardiovascular Risk and Nutrition, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Arós F; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Salas-Salvadó J; Department of Endocrinology, Virgen de la Victoria Hospital, Biomedical Research Institute of Málaga, University of Málaga, Málaga, Spain.
  • Schulze MB; Centro de Investigación Biomédica En Red (CIBER), M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • Martinez-Gonzalez MA; Department of Internal Medicine, Hospital Clinic, Institut d'Investigacions Biomèdiques Augist Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Clin Chem ; 69(3): 283-294, 2023 03 01.
Article en En | MEDLINE | ID: mdl-36683466
BACKGROUND: Plasma fatty acids (FAs) have been associated with cardiovascular disease (CVD) risk. Diet and endogenous metabolism influence the FA profile of the plasma phospholipid (PL) fraction. In the PREDIMED trial, we examined 1-year changes in the FA profile of plasma PL according to a nutritional intervention with Mediterranean diets, either supplemented with extra-virgin olive oil (MedDiet + EVOO) or mixed nuts (MedDiet + nuts), in a high cardiovascular risk population. We also analyzed if 1-year changes in PL FAs were associated with subsequent cardiovascular risk. METHODS: We included 779 participants in our case-cohort study: 185 incident cases and 594 participants in the subcohort (including 31 overlapping cases). The end point was the incidence of CVD. We measured the FAs of plasma PL at baseline and after 1 year of intervention. RESULTS: MedDiet + EVOO increased C17:0 and C20:3n9 in linear regression models [ß coefficientperSD : 0.215 (95% CI, 0.032-0.399) and 0.271 (0.107-0.434), respectively] and decreased 16:1n7 and C22:4n6 [ßperSD: -0.239 (95% CI, -0.416 to -0.061) and -0.287 (95% CI, -0.460 to -0.113), respectively] vs the control group. MedDiet + nuts increased C18:3n3 [ßperSD: 0.382 (95% CI, 0.225 - 0.539)], C18:2n6 [ßper SD: 0.250 (95% CI, 0.073 - 0.428)], C18:0 [ßperSD: 0.268 (95% CI, 0.085-0.452)], and C22:0 [ßper SD: 0.216 (95% CI, 0.031-0.402)]; and decreased the sum of six n6 FAs [ßper SD: -0.147 (95% CI, -0.268 to -0.027)] vs the control group. The 1-year increase in C18:2n6 was inversely associated with the subsequent CVD risk (HRperSD: 0.64 (95% CI, 0.44-0.92)). CONCLUSIONS: MedDiet interventions changed n6 FAs and C16:1n7c; other changes were specific for each group: MedDiet + EVOO increased C17:0 and C20:3n9, and MedDiet + Nuts C18:3n3, C18:2n6, C18:0, and C22:0 FAs.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Dieta Mediterránea Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Dieta Mediterránea Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2023 Tipo del documento: Article País de afiliación: España